Bortezomib-induced Sweet's syndrome
Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced S...
Gespeichert in:
| Veröffentlicht in: | Haematologica (Roma) 2005-12, Vol.90 (12 Suppl), p.ECR43 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 Suppl |
| container_start_page | ECR43 |
| container_title | Haematologica (Roma) |
| container_volume | 90 |
| creator | Van Regenmortel, N Van de Voorde, K De Raeve, H Rombouts, S Van de Velde, A Lambert, J Schroyens, W |
| description | Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_16464758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16464758</sourcerecordid><originalsourceid>FETCH-LOGICAL-p124t-2c6cec7c835a2b8d25805b5a26cc11c65a9497a2fc1b9304e87fded726039dfe3</originalsourceid><addsrcrecordid>eNo1jk1LAzEUAIMgtrb-BSl48BRIXr6PWlorLHjQnkvy8hZW3O6y2SLtr7fQepo5DXPDptIE4N6BnLD7Ur6FABGCu2MTabXVzvgpe3rthpFOXdsk3uzzASkvPn-JxueyKMd9HrqW5uy2jj-FHq6cse169bXc8Orj7X35UvFegh45oEVCh16ZCMlnMF6YdHaLKCVaE4MOLkKNMgUlNHlXZ8oOrFAh16Rm7PHS7Q-ppbzrh6aNw3H3f6v-APdZOf0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bortezomib-induced Sweet's syndrome</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Van Regenmortel, N ; Van de Voorde, K ; De Raeve, H ; Rombouts, S ; Van de Velde, A ; Lambert, J ; Schroyens, W</creator><creatorcontrib>Van Regenmortel, N ; Van de Voorde, K ; De Raeve, H ; Rombouts, S ; Van de Velde, A ; Lambert, J ; Schroyens, W</creatorcontrib><description>Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded.</description><identifier>EISSN: 1592-8721</identifier><identifier>PMID: 16464758</identifier><language>eng</language><publisher>Italy</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Boronic Acids - administration & dosage ; Boronic Acids - adverse effects ; Bortezomib ; Drug Administration Schedule ; Erectile Dysfunction - chemically induced ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Melphalan - administration & dosage ; Methylprednisolone - therapeutic use ; Multiple Myeloma - drug therapy ; Pain - chemically induced ; Peripheral Nervous System Diseases - chemically induced ; Prednisolone - administration & dosage ; Protease Inhibitors - administration & dosage ; Protease Inhibitors - adverse effects ; Pyrazines - administration & dosage ; Pyrazines - adverse effects ; Recurrence ; Sleep Initiation and Maintenance Disorders - chemically induced ; Sweet Syndrome - chemically induced ; Sweet Syndrome - diagnosis ; Sweet Syndrome - drug therapy ; Sweet Syndrome - pathology ; Testicular Diseases - chemically induced</subject><ispartof>Haematologica (Roma), 2005-12, Vol.90 (12 Suppl), p.ECR43</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16464758$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Regenmortel, N</creatorcontrib><creatorcontrib>Van de Voorde, K</creatorcontrib><creatorcontrib>De Raeve, H</creatorcontrib><creatorcontrib>Rombouts, S</creatorcontrib><creatorcontrib>Van de Velde, A</creatorcontrib><creatorcontrib>Lambert, J</creatorcontrib><creatorcontrib>Schroyens, W</creatorcontrib><title>Bortezomib-induced Sweet's syndrome</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Boronic Acids - administration & dosage</subject><subject>Boronic Acids - adverse effects</subject><subject>Bortezomib</subject><subject>Drug Administration Schedule</subject><subject>Erectile Dysfunction - chemically induced</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Melphalan - administration & dosage</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Pain - chemically induced</subject><subject>Peripheral Nervous System Diseases - chemically induced</subject><subject>Prednisolone - administration & dosage</subject><subject>Protease Inhibitors - administration & dosage</subject><subject>Protease Inhibitors - adverse effects</subject><subject>Pyrazines - administration & dosage</subject><subject>Pyrazines - adverse effects</subject><subject>Recurrence</subject><subject>Sleep Initiation and Maintenance Disorders - chemically induced</subject><subject>Sweet Syndrome - chemically induced</subject><subject>Sweet Syndrome - diagnosis</subject><subject>Sweet Syndrome - drug therapy</subject><subject>Sweet Syndrome - pathology</subject><subject>Testicular Diseases - chemically induced</subject><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jk1LAzEUAIMgtrb-BSl48BRIXr6PWlorLHjQnkvy8hZW3O6y2SLtr7fQepo5DXPDptIE4N6BnLD7Ur6FABGCu2MTabXVzvgpe3rthpFOXdsk3uzzASkvPn-JxueyKMd9HrqW5uy2jj-FHq6cse169bXc8Orj7X35UvFegh45oEVCh16ZCMlnMF6YdHaLKCVaE4MOLkKNMgUlNHlXZ8oOrFAh16Rm7PHS7Q-ppbzrh6aNw3H3f6v-APdZOf0</recordid><startdate>200512</startdate><enddate>200512</enddate><creator>Van Regenmortel, N</creator><creator>Van de Voorde, K</creator><creator>De Raeve, H</creator><creator>Rombouts, S</creator><creator>Van de Velde, A</creator><creator>Lambert, J</creator><creator>Schroyens, W</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200512</creationdate><title>Bortezomib-induced Sweet's syndrome</title><author>Van Regenmortel, N ; Van de Voorde, K ; De Raeve, H ; Rombouts, S ; Van de Velde, A ; Lambert, J ; Schroyens, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p124t-2c6cec7c835a2b8d25805b5a26cc11c65a9497a2fc1b9304e87fded726039dfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Boronic Acids - administration & dosage</topic><topic>Boronic Acids - adverse effects</topic><topic>Bortezomib</topic><topic>Drug Administration Schedule</topic><topic>Erectile Dysfunction - chemically induced</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Melphalan - administration & dosage</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Pain - chemically induced</topic><topic>Peripheral Nervous System Diseases - chemically induced</topic><topic>Prednisolone - administration & dosage</topic><topic>Protease Inhibitors - administration & dosage</topic><topic>Protease Inhibitors - adverse effects</topic><topic>Pyrazines - administration & dosage</topic><topic>Pyrazines - adverse effects</topic><topic>Recurrence</topic><topic>Sleep Initiation and Maintenance Disorders - chemically induced</topic><topic>Sweet Syndrome - chemically induced</topic><topic>Sweet Syndrome - diagnosis</topic><topic>Sweet Syndrome - drug therapy</topic><topic>Sweet Syndrome - pathology</topic><topic>Testicular Diseases - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Regenmortel, N</creatorcontrib><creatorcontrib>Van de Voorde, K</creatorcontrib><creatorcontrib>De Raeve, H</creatorcontrib><creatorcontrib>Rombouts, S</creatorcontrib><creatorcontrib>Van de Velde, A</creatorcontrib><creatorcontrib>Lambert, J</creatorcontrib><creatorcontrib>Schroyens, W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Regenmortel, N</au><au>Van de Voorde, K</au><au>De Raeve, H</au><au>Rombouts, S</au><au>Van de Velde, A</au><au>Lambert, J</au><au>Schroyens, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bortezomib-induced Sweet's syndrome</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2005-12</date><risdate>2005</risdate><volume>90</volume><issue>12 Suppl</issue><spage>ECR43</spage><pages>ECR43-</pages><eissn>1592-8721</eissn><abstract>Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded.</abstract><cop>Italy</cop><pmid>16464758</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1592-8721 |
| ispartof | Haematologica (Roma), 2005-12, Vol.90 (12 Suppl), p.ECR43 |
| issn | 1592-8721 |
| language | eng |
| recordid | cdi_pubmed_primary_16464758 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Boronic Acids - administration & dosage Boronic Acids - adverse effects Bortezomib Drug Administration Schedule Erectile Dysfunction - chemically induced Humans Immunosuppressive Agents - therapeutic use Male Melphalan - administration & dosage Methylprednisolone - therapeutic use Multiple Myeloma - drug therapy Pain - chemically induced Peripheral Nervous System Diseases - chemically induced Prednisolone - administration & dosage Protease Inhibitors - administration & dosage Protease Inhibitors - adverse effects Pyrazines - administration & dosage Pyrazines - adverse effects Recurrence Sleep Initiation and Maintenance Disorders - chemically induced Sweet Syndrome - chemically induced Sweet Syndrome - diagnosis Sweet Syndrome - drug therapy Sweet Syndrome - pathology Testicular Diseases - chemically induced |
| title | Bortezomib-induced Sweet's syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A46%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bortezomib-induced%20Sweet's%20syndrome&rft.jtitle=Haematologica%20(Roma)&rft.au=Van%20Regenmortel,%20N&rft.date=2005-12&rft.volume=90&rft.issue=12%20Suppl&rft.spage=ECR43&rft.pages=ECR43-&rft.eissn=1592-8721&rft_id=info:doi/&rft_dat=%3Cpubmed%3E16464758%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16464758&rfr_iscdi=true |